ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Phase 2
Completed
Conditions
First Posted Date
2006-06-15
Last Posted Date
2013-07-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
1108
Registration Number
NCT00337090
Locations
🇷🇺

3 Sites, St Petersburg, Russian Federation

🇸🇪

2 Sites, Stockholm, Sweden

🇷🇺

7 Sites, Moscow, Russian Federation

Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys

First Posted Date
2006-05-03
Last Posted Date
2017-02-24
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
142
Registration Number
NCT00321113

Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-05-03
Last Posted Date
2014-08-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
101
Registration Number
NCT00321074

A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients

Phase 4
Completed
Conditions
Interventions
First Posted Date
2006-04-27
Last Posted Date
2014-08-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
123
Registration Number
NCT00319917

An Open Study for Steroid Resistant, Non-Thymectomized MG Patients

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-03-31
Last Posted Date
2009-06-03
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
11
Registration Number
NCT00309101

FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-03-31
Last Posted Date
2014-08-25
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
80
Registration Number
NCT00309088

Optimizing Prograf® Therapy in Renal Transplant Patients

Phase 4
Completed
Conditions
First Posted Date
2006-03-01
Last Posted Date
2008-08-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
323
Registration Number
NCT00297765
© Copyright 2024. All Rights Reserved by MedPath